Analysts’ Viewpoint
The biologics market is poised for continued growth with several upcoming trends driving innovation. One of the key trends is the surge in demand for personalized medicine, leading to the development of targeted biologic therapies tailored to individual patient profiles.
Advancements in biotechnology, including gene editing and synthetic biology, are opening new avenues for the development of novel biologics with enhanced efficacy and reduced side effects.
The rise of biosimilars, which are highly comparable versions of approved biologics, is expected to fuel market progress by providing more affordable treatment options and fostering competition.
Furthermore, the expansion of biologics into new therapeutic areas such as gene therapy and regenerative medicine is likely to drive biologics market growth.
Biologics are a class of medicinal products derived from living organisms or containing components of living organisms. Unlike traditional chemical drugs, which are synthesized through chemical processes, biologics are typically large, complex molecules such as proteins, nucleic acids, or antibodies that are produced through biotechnological processes involving living cells.
Applications of biologics span across various fields, including medicine, agriculture, and environmental science. In medicine, biologics have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, infectious diseases, and genetic disorders.
| Attribute | Detail |
|---|---|
| Driver | Strong Pipeline with Accelerated Approval |
A robust pipeline and accelerated approval from regulatory bodies is fueling the biologics market size by hastening the development and commercialization of novel therapies. Major pharmaceutical companies such as Pfizer, are actively advancing numerous biologics across various therapeutic indications within their pipelines.
Regulatory agencies, recognizing the critical need for innovative treatments, have introduced pathways for accelerated approval, enabling promising biologics to reach patients more rapidly while still upholding stringent safety and efficacy standards.
For instance, during the COVID-19 pandemic, governments authorized the manufacturing of biological vaccines. In 2021, the World Health Organization (WHO) granted an emergency use listing (EUL) for COVAXIN, developed by Bharat Biotech, expanding the array of vaccines endorsed by WHO for combating COVID-19.
This streamlined process minimizes development timelines and facilitates swifter market entry for biologic therapies aimed at treating various diseases.
Consequently, pharmaceutical companies are intensifying their research and development efforts, particularly in the realm of cell and gene therapies, to expand their biologics pipelines. Although over 1,500 clinical trials for cell and gene therapies are ongoing, the vast majority remain in early phases, indicating a lengthy path to commercialization for most.
Nonetheless, the presence of accelerated approval pathways fosters collaboration between industry and regulatory bodies, creating a supportive environment for innovation and sustaining the growth trajectory of the biologics market.
The biologics market segmentation based on product includes monoclonal antibodies, recombinant proteins, vaccines, cell & gene therapy, and others. The monoclonal antibodies segment is projected to dominate the global market during the forecast period.
Monoclonal antibodies have fewer adverse effects due to their high specificity. Hence, mAbs have become the predominant class of new drugs developed in the last few years.
In the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2022, out of the top five bestselling prescription drugs worldwide two were mAbs -Keytruda (pembrolizumab), and Humira (adalimumab).
The segment’s dominance is primarily ascribed to surge in adoption of monoclonal antibodies for large unmet medical needs in the fields of oncology and autoimmune disorders.
Recombinant proteins are expected to grow at the fastest pace during the forecast period. Recombinant proteins which are also known as highly potent medicines are safe from off-target side effects, and take a shorter time to develop than other biologics.
As per the biologics market analysis, the oncology segment is projected to dominate based on application, during the forecast period. Cancer continues to be one of the leading causes of mortality worldwide. The development of biologics has transformed oncology treatment in recent decades.
A wide range of monoclonal antibodies, therapeutic vaccines, checkpoint inhibitors, and other biologic drugs are now available to treat both solid and blood cancers more effectively. As new targets are discovered, the oncology biologics pipeline is teeming with novel therapies, consequently boosting the global market value.
Some of the top selling oncology biologics include Avastin, Rituxan, Herceptin, Opdivo, and Keytruda. These biologic drugs generated billions in annual sales combined and have greatly improved survival rates for cancer types such as breast, lung, and blood cancers compared to conventional chemotherapy alone.
Given the high prevalence and unmet needs in oncology, biopharma companies prioritize this segment for R&D investment.
The global biologics market trends indicate that the in-house segment is currently dominant, in terms of manufacturing. Large biopharma companies have traditionally favored building internal manufacturing capabilities to maintain high quality standards and confidentiality over their biologic drug development processes.
Developing an in-house manufacturing plant requires huge capital investments but provides long-term control over production.
Smaller biotech companies often lack the resources to establish their own commercial-scale manufacturing facilities from the outset. For early-stage clinical development too, outsourcing production to Contract Development and Manufacturing Organizations (CDMOs) proves more practical and economical.
This has significantly boosted the outsourced segment. For example, many novel CAR-T and gene therapies in development rely entirely on CDMOs for manufacturing scale-up and commercial supply.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest biologics market forecast, the pharmaceutical sector in North America has long been a significant player for new biologics.
Anticancer drugs, as well as enhanced immune class drugs, have been at the forefront of North America’s biologic product development, including cutting-edge technologies such as checkpoint inhibitors (e.g. PD1), chimeric antigen receptor (CAR)-T-cell therapies, antibody drug conjugates (ADCs), and monoclonal antibodies (mAbs).
Asia Pacific also has a significant biologics market share. The region is witnessing substantial investments in healthcare infrastructure, research and development, and biotechnology innovation, particularly in countries such as China, India, and South Korea.
These investments are fostering the development and manufacturing of biologic medicines within the region, offering lucrative biologics industry opportunities.
As per the biologics market report, leading players are focusing on strategies such as new product launches, mergers, partnerships, and collaborations to strengthen their position.
AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and F. Hoffmann-La Roche AG are the prominent biologics market manufacturers.
Each of these players have been profiled in the global biologics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and latest developments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 | US$ 515.6 Bn |
| Market Forecast Value in 2031 | More than US$ 855.8 Bn |
| Growth Rate (CAGR) | 6.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
| Competition Landscape | Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials |
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 515.6 Bn in 2022
It is projected to reach more than US$ 855.8 Bn by the end of 2031
The CAGR is anticipated to be 6.9% from 2023 to 2031
North America is expected to account for largest share from 2023 to 2031
AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and F. Hoffmann-La Roche AG
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biologics Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biologics Market Analysis and Forecasts, 2017–2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Industry Events
5.2. Porter's Five Forces Analysis
5.3. Disease Prevalence & Incidence Rate by Region/Globally
5.4. Regulatory Scenario by Region/Globally
5.5. Value Chain Analysis
5.6. COVID 19 Impact Analysis
6. Global Biologics Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Cell & Gene Therapy
6.3.5. Others
6.4. Market Attractiveness By Product
7. Global Biologics Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2017–2031
7.3.1. Oncology
7.3.2. Autoimmune & Immunological Disorders
7.3.3. Hematological Disorders
7.3.4. Infectious Diseases
7.3.5. Others
7.4. Market Attractiveness By Application
8. Global Biologics Market Analysis and Forecasts, By Manufacturing
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Manufacturing, 2017–2031
8.3.1. Outsourced
8.3.2. In-house
8.4. Market Attractiveness By Manufacturing
9. Global Biologics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Biologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Cell & Gene Therapy
10.2.5. Others
10.3. Market Value Forecast By Application, 2017–2031
10.3.1. Oncology
10.3.2. Autoimmune & Immunological Disorders
10.3.3. Hematological Disorders
10.3.4. Infectious Diseases
10.3.5. Others
10.4. Market Value Forecast By Manufacturing, 2017–2031
10.4.1. Outsourced
10.4.2. In-house
10.5. Market Value Forecast By Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Manufacturing
10.6.4. By Country
11. Europe Biologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Cell & Gene Therapy
11.2.5. Others
11.3. Market Value Forecast By Application, 2017–2031
11.3.1. Oncology
11.3.2. Autoimmune & Immunological Disorders
11.3.3. Hematological Disorders
11.3.4. Infectious Diseases
11.3.5. Others
11.4. Market Value Forecast By Manufacturing, 2017–2031
11.4.1. Outsourced
11.4.2. In-house
11.5. Market Value Forecast By Country, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Manufacturing
11.6.4. By Country/Sub-region
12. Asia Pacific Biologics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Product, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Cell & Gene Therapy
12.2.5. Others
12.3. Market Value Forecast By Application, 2017–2031
12.3.1. Oncology
12.3.2. Autoimmune & Immunological Disorders
12.3.3. Hematological Disorders
12.3.4. Infectious Diseases
12.3.5. Others
12.4. Market Value Forecast By Manufacturing, 2017–2031
12.4.1. Outsourced
12.4.2. In-house
12.5. Market Value Forecast By Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of APAC
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Manufacturing
12.6.4. By Country/Sub-region
13. Latin America Biologics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Recombinant Proteins
13.2.3. Vaccines
13.2.4. Cell & Gene Therapy
13.2.5. Others
13.3. Market Value Forecast By Application, 2017–2031
13.3.1. Oncology
13.3.2. Autoimmune & Immunological Disorders
13.3.3. Hematological Disorders
13.3.4. Infectious Diseases
13.3.5. Others
13.4. Market Value Forecast By Manufacturing, 2017–2031
13.4.1. Outsourced
13.4.2. In-house
13.5. Market Value Forecast By Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of LATAM
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Manufacturing
13.6.4. By Country/Sub-region
14. Middle East & Africa Biologics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Recombinant Proteins
14.2.3. Vaccines
14.2.4. Cell & Gene Therapy
14.2.5. Others
14.3. Market Value Forecast By Application, 2017–2031
14.3.1. Oncology
14.3.2. Autoimmune & Immunological Disorders
14.3.3. Hematological Disorders
14.3.4. Infectious Diseases
14.3.5. Others
14.4. Market Value Forecast By Manufacturing, 2017–2031
14.4.1. Outsourced
14.4.2. In-house
14.5. Market Value Forecast By Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of MEA
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By Manufacturing
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Share Analysis By Company (2022)
15.2. Company Profiles
15.2.1. AbbVie, Inc.
15.2.1.1. Company Overview
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. Business Strategies
15.2.1.5. Recent Developments
15.2.2. Amgen
15.2.2.1. Company Overview
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. Business Strategies
15.2.2.5. Recent Developments
15.2.3. AstraZeneca
15.2.3.1. Company Overview
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. Business Strategies
15.2.3.5. Recent Developments
15.2.4. Bristol-Myers Squibb Company
15.2.4.1. Company Overview
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. Business Strategies
15.2.4.5. Recent Developments
15.2.5. Eli Lilly
15.2.5.1. Company Overview
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. Business Strategies
15.2.5.5. Recent Developments
15.2.6. Gilead Sciences, Inc.
15.2.6.1. Company Overview
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. Business Strategies
15.2.6.5. Recent Developments
15.2.7. GlaxoSmithKline
15.2.7.1. Company Overview
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. Business Strategies
15.2.7.5. Recent Developments
15.2.8. Johnson & Johnson Services, Inc.
15.2.8.1. Company Overview
15.2.8.2. Financial Overview
15.2.8.3. Product Portfolio
15.2.8.4. Business Strategies
15.2.8.5. Recent Developments
15.2.9. Merck & Co. Inc.
15.2.9.1. Company Overview
15.2.9.2. Financial Overview
15.2.9.3. Product Portfolio
15.2.9.4. Business Strategies
15.2.9.5. Recent Developments
15.2.10. Novartis AG
15.2.10.1. Company Overview
15.2.10.2. Financial Overview
15.2.10.3. Product Portfolio
15.2.10.4. Business Strategies
15.2.10.5. Recent Developments
15.2.11. Pfizer, Inc.
15.2.11.1. Company Overview
15.2.11.2. Financial Overview
15.2.11.3. Product Portfolio
15.2.11.4. Business Strategies
15.2.11.5. Recent Developments
15.2.12. F. Hoffmann-La Roche Ltd
15.2.12.1. Company Overview
15.2.12.2. Financial Overview
15.2.12.3. Product Portfolio
15.2.12.4. Business Strategies
15.2.12.5. Recent Developments
List of Tables
Table 01: Global Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 02: Global Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 03: Global Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031
Table 04: Global Biologics Market Value (US$ Bn) Forecast, by Region, 2017–2031
Table 05: North America Biologics Market Value (US$ Bn) Forecast, by Country, 2017–2031
Table 06: North America Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 07: North America Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 08: North America Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031
Table 09: Europe Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 11: Europe Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 12: Europe Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031
Table 13: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 15: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 16: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031
Table 17: Latin America Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 19: Latin America Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 20: Latin America Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031
Table 21: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031
Table 23: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031
Table 24: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031
List of Figures
Figure 01: Global Biologics Market Value (US$ Bn) Forecast, 2017–2031
Figure 02: Global Biologics Market Value Share, by Product, 2022
Figure 03: Global Biologics Market Value Share, by Application, 2022
Figure 04: Global Biologics Market Value Share, by Manufacturing, 2022
Figure 05: Global Biologics Market Value Share, by Region, 2022
Figure 06: Global Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031
Figure 07: Global Biologics Market Share Analysis, by Product, 2022
Figure 08: Global Biologics Market Share Analysis, by Product, 2031
Figure 09: Global Biologics Market Attractiveness Analysis, by Product, 2023–2031
Figure 10: Global Biologics Market Value (US$ Bn), by Monoclonal Antibodies, 2017–2031
Figure 11: Global Biologics Market Value Share Analysis, by Monoclonal Antibodies, 2022–2031
Figure 12: Global Biologics Market Value (US$ Bn), by Recombinant Proteins, 2017–2031
Figure 13: Global Biologics Market Value Share Analysis, by Recombinant Proteins, 2022–2031
Figure 14: Global Biologics Market Value (US$ Bn), by Vaccines, 2017–2031
Figure 15: Global Biologics Market Value Share Analysis, by Vaccines, 2022–2031
Figure 16: Global Biologics Market Value (US$ Bn), by Cell & Gene Therapy, 2017–2031
Figure 17: Global Biologics Market Value Share Analysis, by Cell & Gene Therapy, 2022–2031
Figure 18: Global Biologics Market Value (US$ Bn), by Others, 2017–2031
Figure 19: Global Biologics Market Value Share Analysis, by Others, 2022–2031
Figure 20: Global Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031
Figure 21: Global Biologics Market Share Analysis, by Application, 2022
Figure 22: Global Biologics Market Share Analysis, by Application, 2031
Figure 23: Global Biologics Market Attractiveness Analysis, by Application, 2023–2031
Figure 24: Global Biologics Market Value (US$ Bn), by Oncology, 2017–2031
Figure 25: Global Biologics Market Value Share Analysis, by Oncology, 2022–2031
Figure 26: Global Biologics Market Value (US$ Bn), by Autoimmune & Immunological Disorders, 2017–2031
Figure 27: Global Biologics Market Value Share Analysis, by Autoimmune & Immunological Disorders, 2022–2031
Figure 28: Global Biologics Market Value (US$ Bn), by Hematological Disorders, 2017–2031
Figure 29: Global Biologics Market Value Share Analysis, by Hematological Disorders, 2022–2031
Figure 30: Global Biologics Market Value (US$ Bn), by Infectious Diseases, 2017–2031
Figure 31: Global Biologics Market Value Share Analysis, by Infectious Diseases, 2022–2031
Figure 34: Global Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031
Figure 35: Global Biologics Market Share Analysis, by Manufacturing, 2022
Figure 36: Global Biologics Market Share Analysis, by Manufacturing, 2031
Figure 37: Global Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031
Figure 38: Global Biologics Market Value (US$ Bn), by Outsourced, 2017–2031
Figure 39: Global Biologics Market Value Share Analysis, by Outsourced, 2022–2031
Figure 40: Global Biologics Market Value (US$ Bn), by In-house, 2017–2031
Figure 41: Global Biologics Market Value Share Analysis, by In-house, 2022–2031
Figure 42: Global Biologics Market Value Share Analysis, by Region, 2022–2031
Figure 43: Global Biologics Market Share Analysis, by Region, 2022
Figure 44: Global Biologics Market Share Analysis, by Region, 2031
Figure 45: Global Biologics Market Attractiveness Analysis, by Region, 2023–2031
Figure 46: North America Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 47: North America Biologics Market Value Share Analysis, by Country, 2022–2031
Figure 48: North America Biologics Market Attractiveness Analysis, by Country, 2023–2031
Figure 49: North America Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031
Figure 50: North America Biologics Market Attractiveness Analysis, by Product, 2023–2031
Figure 51: North America Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031
Figure 52: North America Biologics Market Attractiveness Analysis, by Application, 2023–2031
Figure 53: North America Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031
Figure 54: North America Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031
Figure 55: Europe Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 56: Europe Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Europe Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 58: Europe Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031
Figure 59: Europe Biologics Market Attractiveness Analysis, by Product, 2023–2031
Figure 60: Europe Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031
Figure 61: Europe Biologics Market Attractiveness Analysis, by Application, 2023–2031
Figure 62: Europe Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031
Figure 63: Europe Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031
Figure 64: Asia Pacific Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 65: Asia Pacific Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 66: Asia Pacific Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 67: Asia Pacific Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031
Figure 68: Asia Pacific Biologics Market Attractiveness Analysis, by Product, 2023–2031
Figure 69: Asia Pacific Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031
Figure 70: Asia Pacific Biologics Market Attractiveness Analysis, by Application, 2023–2031
Figure 71: Asia Pacific Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031
Figure 72: Asia Pacific Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031
Figure 73: Latin America Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 74: Latin America Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 75: Latin America Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 76: Latin America Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031
Figure 77: Latin America Biologics Market Attractiveness Analysis, by Product, 2023–2031
Figure 78: Latin America Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031
Figure 79: Latin America Biologics Market Attractiveness Analysis, by Application, 2023–2031
Figure 80: Latin America Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031
Figure 81: Latin America Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031
Figure 82: Middle East & Africa Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 83: Middle East & Africa Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 84: Amgen Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2019–2022
Figure 84: Middle East & Africa Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 85: Amgen Inc. Breakdown of Net Sales (%), by Region/Country, 2022
Figure 85: Middle East & Africa Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031
Figure 86: Amgen Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2019–2022
Figure 86: Middle East & Africa Biologics Market Attractiveness Analysis, by Product, 2023–2031
Figure 87: Middle East & Africa Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031
Figure 88: Middle East & Africa Biologics Market Attractiveness Analysis, by Application, 2023–2031
Figure 89: Middle East & Africa Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031
Figure 90: Middle East & Africa Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Biologics Market
